Clinical trials: Stevens-Johnson Syndrome
Pterygium, Ocular Surface Disease
Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation
To evaluate the use of cultivated conjunctival epithelial equivalents for the treatment of ocular diseases
- Conditions
- Pterygium, Ocular Surface Disease, Stevens Johnson Syndrome, Chemical Injury
- Trial name
- NCT00346450
- Testing
- Cultivated conjunctival transplantation
- Where
- Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Singapore National Eye Centre
Rare Diseases, Toxic Epidermal Necrolyses
Severe Bullous Drug Eruption and Filgrastim
Toxic epidermal necrolysis (TEN) including Stevens Johnson (SJS) and Lyell syndromes represent the most severe drug eruptions. It is an allergic disorder caused by cytotoxic T lymphocytes, specific of drugs, responsible for the…
- Trial name
- GNET (NCT04651439)
- Testing
- Filgrastim
- Where
- 3 sites in France
- Volunteers
- 42 people
- Sponsor
- Hospices Civils de Lyon
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria.
- Trial name
- NCT01696500
- Testing
- Intravenous immunoglobulin
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Penetrating Keratoplasty, Multiple Graft Failure
Subconjunctival Humira for Boston Keratoprosthesis
This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.
- Conditions
- Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
- Trial name
- NCT06926478
- Testing
- Adalimumab Injection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Cicatrizing Conjunctivitis, Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis
This is a prospective study that aimed to observe the therapeutic effects of minor salivary gland transplantation for cicatrizing conjunctivitis patients.
- Conditions
- Cicatrizing Conjunctivitis, Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum, Sjogren Syndrome, Mucous Membrane Pemphigoid
- Trial name
- NCT03839069
- Testing
- minor salivary gland transplantation
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Stevens-Johnson Syndrome, Drug Reaction With Eosinophilia and Systemic Symptom
Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study
Serum vitamin D levels in drug-induced non-immediate reactions
- Conditions
- Stevens-Johnson Syndrome, Drug Reaction With Eosinophilia and Systemic Symptom, Maculopapular Exanthem, Vitamin D Deficiency
- Trial name
- NCT06263140
- Where
- Thailand
- Volunteers
- 120 people
- Sponsor
- Chulalongkorn University
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
NATIENS: Optimal Management and Mechanisms of SJS/TEN
The North American Therapeutics in Epidermal Necrolysis Syndrome (NATIENS) study is a multicenter double-blind randomized controlled assessment of two arms - one of systemic immunomodulatory therapy (etanercept) and one of…
- Trial name
- NATIENS (NCT02987257)
- Testing
- Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
- Where
- 14 sites in United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt University Medical Center
Symblepharon, Dry Eye
Salivary Gland Transplantation in the Treatment of Dry Eye in Patients With Stevens-Johnson Syndrome.
The purpose of this study is to evaluate salivary gland and labial mucous membrane transplantation in patients with severe symblepharon and dry eye secondary to Stevens-Johnson Syndrome (SJS).
- Conditions
- Symblepharon, Dry Eye, Ocular Surface Disease, Transplantation
- Trial name
- NCT01178242
- Testing
- Salivary Gland and Labial Mucous Membrane Transplantation
- Where
- Brazil
- Volunteers
- 19 people
- Sponsor
- Federal University of São Paulo
Graft vs Host Disease, Congenital Aniridia
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely.
- Conditions
- Graft vs Host Disease, Congenital Aniridia, Chemical Burns, Stevens-Johnson Syndrome
- Trial name
- NCT02945176
- Testing
- ARGOS-IO system
- Where
- 2 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Chemical Injuries, Unspecified Complication of Corneal Transplant
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
The purpose of the pilot study is to test the efficacy and safety of riboflavin/Ultraviolet A (UVA) cross-linked human donor corneas as carriers for the Boston Keratoprosthesis (Boston KPro) in patients with higher risk for…
- Conditions
- Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid
- Trial name
- NCT01582880
- Testing
- Riboflavin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Joseph B. Ciolino, MD
Stevens - Johnson Syndrome
G-CSF in the Treatment of Toxic Epidermal Necrolysis
NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial.
- Trial name
- NeupoNET (NCT02739295)
- Testing
- recombinant granulocyte - colony stimulating factor, NaCl 0.9%
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- University of Liege
Stevens-Johnson Syndrome
Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye
The purpose of this study is to evaluate the efficacy of 0.05% cyclosporin ophthalmic emulsion (Restasis) in patients with Stevens-Johnson syndrome that have dry eyes by subjective symptoms and signs.
- Trial name
- NCT01488396
- Testing
- 0.05%cyclosporin eye drop
- Where
- Thailand
- Volunteers
- 31 people
- Sponsor
- Mahidol University
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
The investigators' aim is to study the effects of mechanical expression of meibomian glands on eyelid disease, ocular surface health in the subacute phase of SJS/TEN.
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis
- Trial name
- NCT05145959
- Testing
- Maskin Probe
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Toxic Epidermal Necrolysis
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.
- Trial name
- NCT00372723
- Testing
- Remicaide (infliximab)
- Sponsor
- Loyola University
Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced
SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a severe adverse drug reaction, characterized by extensive skin detachment.
- Conditions
- Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced, Toxic Epidermal Necrolysis Due to Drug
- Trial name
- NCT06522048
- Testing
- Observational studies do not require intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chao Ji
GVHD, Meibomian Gland Dysfunction (Disorder)
Autologous Serum Obtained by a Closed-Circuit Collection Device
Autologous serum eye drops (ASED) are an established therapy for ocular surface diseases; however, their preparation can be costly and may not be available due to the need for germ-free conditions.
- Conditions
- GVHD, Meibomian Gland Dysfunction (Disorder), Stevens-Johnson Syndrome, Limbal Keratoconjunctivitis
- Trial name
- NCT07014059
- Testing
- Autologous Serum 20%
- Where
- Brazil
- Volunteers
- 16 people
- Sponsor
- GIANCARLO FATOBENE
Inflammatory Response, Multi Organ Failure
Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients
This study will involve blood draws to test for specific cytokines. The study goal is to gain a better understanding of the role of inflammatory response in the development of specific complications in burn and TENS patients.
- Conditions
- Inflammatory Response, Multi Organ Failure, Nosocomial Infection, Deep Vein Thrombosis
- Trial name
- NCT04252651
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Joseph M. Still Research Foundation, Inc.
Stevens-Johnson Syndrome, Corneal Blindness
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
The proposed study is intended to test the idea, based upon current knowledge of the biology and physiology of corneal ulceration in SJS/TENS patients who receive a keratoprosthesis, and on the known effects of infliximab on…
- Trial name
- NCT01256489
- Testing
- Infliximab
- Where
- United States
- Sponsor
- Massachusetts Eye and Ear Infirmary
Toxic Epidermal Necrolysis
Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study
The purpose of this study is to determine whether isotretinoin is helpful in treating patients with an adverse cutaneous drug eruption known as toxic epidermal necrolysis (TEN).
- Trial name
- NCT02795143
- Testing
- Isotretinoin
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Toxic Epidermal Necrolysis
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
The primary objectives of this study are to investigate the efficacy and safety of topical steroid ointment (clobetasol 0.05%) for the treatment of the cutaneous manifestations of toxic epidermal necrolysis (TEN).
- Trial name
- TEN (NCT02319616)
- Testing
- Clobetasol 0.05% ointment
- Where
- United States
- Sponsor
- University of California, Davis